Skip to main content
S&P 5007,580.07-1.82%DOW51,770.31-1.09%NASDAQ25,437.00-2.86%BTC$77,415.00+0.36%ETH$2,246.32+1.22%GOLD$3,884.90-3.63%OIL$102.95+0.93%
Smart Investors Daily
SID Premium
Gilead Sciences, Inc. logo

NASDAQ · GILD

Gilead Sciences, Inc.

Healthcare · Drug Manufacturers - General

$165.61

Up+$5.07 (+3.06%)

Updated Oct 31, 2026, 12:42 AM

SID Score

7.6/10

Composite research score

Smart Money

44/100

Neutral

Market cap
152.89B
P/E ratio
18.89
Dividend yield
2.37%
52-week range
$118.22 – $165.70
Volume
8.43M
Avg. volume
7.34M

Price performance · GILD

GILD price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 29, 2026

GILD closed at $165.61 after 20 trading sessions, up 14.42% for the selected period.

Last close
$165.61
Period change
+14.42%
Period low
$144.23
Period high
$165.61
Daily close
View OHLC price history
GILD OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 29, 2026$162.89$165.70$160.86$165.618.43M
Oct 28, 2026$157.28$160.83$156.04$159.205M
Oct 27, 2026$156.05$159.28$155.76$159.084.93M
Oct 26, 2026$157.62$159.69$157.5201$158.696.05M
Oct 23, 2026$156.47$157.65$155.76$156.046.07M
Oct 22, 2026$154.24$157.42$153.00$157.196.21M
Oct 21, 2026$154.73$155.42$151.71$153.576.22M
Oct 20, 2026$155.37$157.48$154.02$156.515.79M
Oct 19, 2026$155.385$157.24$152.92$153.076.84M
Oct 16, 2026$157.32$157.575$155.62$156.197.77M
Oct 15, 2026$156.39$160.51$156.02$157.378.29M
Oct 14, 2026$148.19$153.76$147.48$153.545.76M
Oct 13, 2026$151.16$151.16$147.26$147.926.23M
Oct 12, 2026$151.835$152.26$149.80$150.435.79M
Oct 9, 2026$147.23$151.44$146.10$151.175.8M
Oct 8, 2026$146.73$147.59$144.65$147.104.49M
Oct 7, 2026$145.275$148.60$144.85$146.855.1M
Oct 6, 2026$145.11$146.14$142.5982$144.233.72M
Oct 5, 2026$143.21$145.16$142.79$144.636.14M
Oct 2, 2026$147.65$148.00$144.00$144.745.04M

Latest GILD news

The latest Smart Investors Daily articles mentioning GILD.

Stock researchCompany · Overview

GILD research

Overview

Company profile and research snapshot.

Company profile

Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$130.64
Implied upside
—
Analysts
16
GILD recent ratings
DateFirmRatingTarget
Oct 20, 2026B of A SecuritiesBuy—
Oct 8, 2026RBC CapitalSector Perform—
Oct 8, 2026Cantor FitzgeraldOverweight—
Oct 7, 2026JP MorganOverweight—
Oct 7, 2026Truist SecuritiesBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 24, 2026

Gilead Sciences (GILD) Could Be 22% Overvalued Following Its Liver Meeting Update

Gilead Sciences (GILD) is back in focus after outlining new data it plans to showcase at The Liver Meeting 2026 on its liver disease drugs Livdelzi and Hepcludex, drawing fresh attention to the depth of its pipeline. Recent news has landed against a strong run in Gilead Sciences’ shares, with the 90 day share price return of 20.67% and year to date gain of 28.32% lifting the stock to US$156.04. The 5 year total shareholder return of 187.39% points to sustained momentum rather than a short...

Yahoo · Oct 23, 2026

The Lanier Law Firm Supports Attorney General Ken Paxton in Reaching $45 Million Settlement with Gilead in Unlawful Inducement Scheme

HOUSTON, October 23, 2026--Building on decades of holding pharmaceutical companies responsible for dangerous products and unlawful business practices, The Lanier Law Firm played a pivotal role supporting Texas Attorney General Ken Paxton in securing a $45 million settlement with Gilead Sciences, Inc. Announced on Oct. 22, the settlement resolves claims that the company offered illegal incentives to medical providers to prescribe its drugs over competitors’ medications.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By